Converge Bio raises $25 million for drug discovery

Converge Bio raised $25 million in its latest funding round. Bessemer Venture Partners led the investment. Several top leaders from Meta and OpenAI also joined in.

The company uses artificial intelligence to find new drugs faster. Their goal is to make the process of creating medicine more accurate. They want to cut down the time it takes to get treatments to patients.

This cash will help the team grow their staff. They also plan to improve their technology. It is a big step for a young company in the medical field.